Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672736 · ClinicalTrials.gov registry record · Phase 1
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
A Phase 1 study, sponsored by University Health Network, Toronto.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01672736 is a Phase 1 study that was terminated before completion, run by University Health Network, Toronto. The registered enrollment target is 19 participants.
The verdict
NCT01672736, a Phase 1 study, was terminated before completion, sponsored by University Health Network, Toronto.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with bortezomib and dexamethasone at the MTD to establish the ORR. This trial will accrue patients with relapsed or relapsed/refractory MM - a disease state for which bortezomib is approved to treat by the FDA and Health Canada. The combination of ASP7487 (OSI-906) with bortezomib is supported by pre-clinical work in MM in which the combination with an IGF1-R inhibitor enhances anti-tumor activity of bortezomib.
Interventions
- DRUG ASP7487, Velcade, Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672736
The ClinicalTrials.gov registry entry for NCT01672736 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASP7487, Velcade, Dexamethasone is the first listed.
NCT01672736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672736 about?
NCT01672736 is a clinical study titled "A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma". This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with bortezomib and dexamethas...
What is the current status of trial NCT01672736?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-09. Estimated completion is 2017-12-27.
What interventions are being tested in trial NCT01672736?
The interventions under investigation include: ASP7487, Velcade, Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01672736?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.